RxDoctor Payments Data

Michael Peimer, MD

Internal Medicine · Chestertown, MDNPI 1306840939

Payments from drug & device makers

$2,846in general payments, 2019–2025

Across 157 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$975
  • Lilly USA, LLC$346
  • AstraZeneca$291
  • Pfizer$272
  • GSK$247
  • Johnson & Johnson$126
  • plus $589 from 13 others

What the payments were for

  • Food & beverage$2,82399%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,846 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$65,399
Medicare patients
118
Services billed
1,687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban84$69,361
MounjaroTirzepatide51$55,607
XareltoRivaroxaban24$26,815
JanuviaSitagliptin Phosphate17$14,641
MyrbetriqMirabegron11$5,663
Ezetimibe115$4,727
Atorvastatin Calcium132$2,752
Rosuvastatin Calcium91$1,604
Metoprolol Succinate74$1,389
Tamsulosin Hcl78$1,314
Amlodipine Besylate66$1,000
Losartan Potassium64$974
Potassium Chloride35$958
Levothyroxine Sodium90$924
Omeprazole36$916

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$272$69,36184 claims
Lilly USA, LLCMounjaro$346$55,60751 claims
Johnson & JohnsonXarelto$126$26,81524 claims
MerckJanuvia$14$14,64117 claims
Astellas Pharma US IncMyrbetriq$45$5,66311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Chestertown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →